{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/d216e525-3568-4f94-b402-8a3eaa1ad260/d8c9e881-440c-4649-8a17-ee4b031160a9?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"TRIM63 as a biomarker for MiT family RCC","description":"<p>In this episode Dr. Rohit Mehra of University of Michigan discusses the utility of TRIM63 as a diagnostic marker to distinguish MiTF-RCC from other renal tumor subtypes with overlapping morphology. In combination with TFE3/TFEB FISH, TRIM63 RNA-ISH assays can improve the accuracy and efficiency of MiTF-RCC diagnosis.</p><p>Study by Mehra et al, <em>TRIM63</em>&nbsp;is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. Modern Pathology, 34, 1596-1607, 2021. https://www.nature.com/articles/s41379-021-00803-z.</p>","author_name":"Modern Pathology"}